Latest GILD news

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?

Zacks Investment Research · Mon, 21 Sep 2026 12:56:04 -0400

Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.

Latin America's PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF

Business Wire · Thu, 17 Sep 2026 18:36:00 -0400

MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society. AHF was among the first organizations to mobilize around concerns that the initial Gilead-.

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Zacks Investment Research · Thu, 17 Sep 2026 10:01:11 -0400

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America

Zacks Investment Research · Wed, 16 Sep 2026 11:31:01 -0400

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

Business Wire · Wed, 16 Sep 2026 08:30:00 -0400

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the.

Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances

MarketBeat · Tue, 15 Sep 2026 14:02:50 -0400

Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O'Day describing the company as being at an “inflection point in value.”

Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · Tue, 15 Sep 2026 13:11:38 -0400

Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Market information is provided for research and visualization and is not investment advice.